The groups, which hold multi-million dollar budgets and a large amount of influence on Capitol Hill[AC1], have stayed quiet for one simple reason: drug companies give them millions of dollars a year in donations. When the advocacy groups do speak up, they usually address the quality of medications, not the price, reports The New York Times.
Advocacy groups are less likely to take stances that could hurt a drug company’s business, said Diana Zuckerman, president of the National Center for Health Research, a Washington, D.C.-based nonprofit that does not accept donations from industry. “I’ve found almost none that are focused on the public health issues of affordable healthcare, affordable insurance, a sustainable system,” she said.
Critics of the advocacy group believe they are not upholding their patient advocacy duties by avoiding conversations about high drug costs.
“It is a conflict of interest, because the interests of the pharmaceutical industry, from whom they are getting support, may be different from the interests of the patients,” said Michael Carome, MD, director of the Health Research Group at Public Citizen, a Washington, D.C.-based consumer advocacy group.
More articles on supply chain:
Medical hackers develop $30 homemade ‘EpiPencil’
Insiders: Wal-Mart considering up to $1B investment in online retailer Flipkart
Supply chain tip of the week: Organizing your value analysis program – less is more
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.